DENTSPLY SIRONA (XRAY) stock is in focus after the company reported second quarter 2026 results, reiterated full year net sales guidance of US$3.5b to US$3.6b, and updated progress on its long running share repurchase program.

The earnings beat and confirmed 2026 sales outlook arrived alongside a sharp move in DENTSPLY SIRONA’s share price, with a 1 day share price return that declined 7.97% and a 3 year total shareholder return that declined 66.12%. This suggests shorter term momentum contrasts with much weaker multi year outcomes.

If this earnings update has you rethinking where growth could come from in healthcare, it may be worth checking out a broader set of dental and medical leaders through the 20 top founder-led companies

DENTSPLY SIRONA shares have dropped again despite an earnings beat and confirmed 2026 sales guidance. Given the long slump in multi year returns, does the current valuation still offer a worthwhile risk reward for new buyers?

Most Popular Narrative: 9.6% Undervalued

Based on the most followed narrative, DENTSPLY SIRONA's fair value of $13.40 sits above the last close at $12.12. This frames the current pullback against a modest implied upside anchored to detailed earnings and margin assumptions.

The analysts have a consensus price target of $13.4 for DENTSPLY SIRONA based on their expectations of its future earnings growth, profit margins and other risk factors.

In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $3.8 billion, earnings will come to $189.7 million, and it would be trading on a PE ratio of 18.8x, assuming you use a discount rate of 9.5%.

Curious what sits behind that valuation gap for DENTSPLY SIRONA? The narrative leans heavily on a profit swing, firmer margins, and a future earnings multiple that assumes steady rather than spectacular revenue progress. Want to see how those pieces fit together and which assumptions do most of the heavy lifting in the fair value math?

Result: Fair Value of $13.40 (UNDERVALUED)

However, the DENTSPLY SIRONA narrative still hinges on higher profit margins and smoother execution, while ongoing sales pressure and tariff costs could easily upset that path.

Next Steps

If the mixed sentiment around DENTSPLY SIRONA leaves you unsure, take a closer look at the numbers now and decide how you feel about the 3 key rewards

Looking for more investment ideas beyond DENTSPLY SIRONA?

If DENTSPLY SIRONA has sharpened your focus, do not stop here. Broaden your watchlist now so you are not relying on a single story.

• Target potential mispricings by scanning companies that appear overlooked on fundamentals through the 49 high quality undervalued stocks
• Prioritise resilience by reviewing companies highlighted in the 78 resilient stocks with low risk scores
• Spot early opportunities before they hit the spotlight by using the screener containing 19 high quality undiscovered gems

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.